The objective of the proposed studies is to identify interactions responsible for selective metabolism by cytochrome P450 2A13, a human lung-specific enzyme. 2A13 has the highest known activity for activation of 4-(methylnitrosamino)-1-(3-pyridy!)-1-butanone (NNK), a primary carcinogen in tobacco. In vivo decreases in 2A13 activity have been correlated with substantial reductions in human lung adenocarcinoma, suggesting selective inhibition of 2A13 as a potential chemoprevention strategy. Design of selective inhibitors requires structural information that is lacking for P450s involved in procarcinogen activation, including 2A13. Earlier studies on the structure and function of drug-metabolizing hepatic P450s have identified a general set of active site residues whose molecular characteristics define substrate specificity. The central hypothesis of this proposal is that specific interactions between one or more of the corresponding 2A13 active site residues and preferred 2A13 substrates precisely dictate metabolism by 2A13. This hypothesis will be tested by a combination of experimental approaches, including site-directed mutagenesis, heterologous expression in E. coli, a variety of functional assays and enzyme inhibition studies, and X-ray crystallography. The individual specific aims are to: 1) determine X-ray crystal structures of 2A13, 2) define the contributions of individual active site and naturally polymorphic residues to 2A13 protein structure and function, and 3) evaluate the selectivity of known and suspected family 2A inhibitors for 2A13 versus 2A6. The research proposed in this application is significant because it is expected to generate new and important information on the specific interactions of extrahepatic cytochromes P450 with their ligands. These results may provide an improved scientific basis for understanding the differential substrate selectivity of related P450s in lung and liver and the molecular results of procarcinogen activation. The ultimate goal is to develop and evaluate chemoprevention strategies via 2A13 inhibition. The proposed research is expected to elucidate structural and functional differences between a lung enzyme that activates tobacco carcinogens and a closely-related liver enzyme that removes foreign chemicals from the body. These differences could be exploited to understand differences in cancer risk between individuals and to develop methods to prevent tobacco-associated lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM076343-03
Application #
7336834
Study Section
Macromolecular Structure and Function A Study Section (MSFA)
Program Officer
Okita, Richard T
Project Start
2006-01-01
Project End
2010-12-31
Budget Start
2008-01-01
Budget End
2008-12-31
Support Year
3
Fiscal Year
2008
Total Cost
$270,737
Indirect Cost
Name
University of Kansas Lawrence
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
076248616
City
Lawrence
State
KS
Country
United States
Zip Code
66045
Yadav, Rahul; Petrunak, Elyse M; Estrada, D Fernando et al. (2017) Structural insights into the function of steroidogenic cytochrome P450 17A1. Mol Cell Endocrinol 441:68-75
Chan, Jeannine; Oshiro, Tyler; Thomas, Sarah et al. (2016) Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole. Drug Metab Dispos 44:534-43
Scott, Emily E; Wolf, C Roland; Otyepka, Michal et al. (2016) The Role of Protein-Protein and Protein-Membrane Interactions on P450 Function. Drug Metab Dispos 44:576-90
Estrada, D Fernando; Skinner, Andria L; Laurence, Jennifer S et al. (2014) Human cytochrome P450 17A1 conformational selection: modulation by ligand and cytochrome b5. J Biol Chem 289:14310-20
Johnson, Eric F; Connick, J Patrick; Reed, James R et al. (2014) Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges. Drug Metab Dispos 42:9-22
Petrunak, Elyse M; DeVore, Natasha M; Porubsky, Patrick R et al. (2014) Structures of human steroidogenic cytochrome P450 17A1 with substrates. J Biol Chem 289:32952-64
Conner, Kip P; Schimpf, Alina M; Cruce, Alex A et al. (2014) Strength of axial water ligation in substrate-free cytochrome P450s is isoform dependent. Biochemistry 53:1428-34
Estrada, D Fernando; Laurence, Jennifer S; Scott, Emily E (2013) Substrate-modulated cytochrome P450 17A1 and cytochrome b5 interactions revealed by NMR. J Biol Chem 288:17008-18
Blake, Linda C; Roy, Anuradha; Neul, David et al. (2013) Benzylmorpholine analogs as selective inhibitors of lung cytochrome P450 2A13 for the chemoprevention of lung cancer in tobacco users. Pharm Res 30:2290-302
Walsh, Agnes A; Szklarz, Grazyna D; Scott, Emily E (2013) Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J Biol Chem 288:12932-43

Showing the most recent 10 out of 21 publications